2. Search Result
Search Result
Results for "

Allograft mouse model

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131598C
    6-Thio-GTP tetrasodium

    6-Thioguanosine-5'-triphosphate tetrasodium

    		 Ras Inflammation/Immunology
    6-Thio-GTP (tetrasodium) is a Vav1-Rac inhibitor. 6-Thio-GTP (tetrasodium) inhibits TCR-stimulated T cell proliferation and CD28-mediated T cell survival. 6-Thio-GTP (tetrasodium) has an immunosuppressive effect in a mouse cardiac allograft transplant model and prolongs cardiac allograft survival .
    6-Thio-GTP tetrasodium
  • HY-P990215
    Anti-Mouse IL-27 p28 Antibody (MM27.7B1)

    		Interleukin Related Infection Inflammation/Immunology
    Anti-Mouse IL-27 p28 Antibody (MM27.7B1) is a mouse-derived anti-mouse IL-27 p28 IgG2a, κ type antibody inhibitor. Anti-Mouse IL-27 p28 Antibody (MM27.7B1) can neutralize IL-27. Anti-Mouse IL-27 p28 Antibody (MM27.7B1) delays CD8+ T cell reconstitution mediated by IL-27 after murine anti-thymocyte globulin (mATG) treatment in BALB/c heart allografts mice models .
    Anti-Mouse IL-27 p28 Antibody (MM27.7B1)
  • HY-175846
    TQFL13

    		Drug Derivative Apoptosis Cancer
    TQFL13 is derivative of Thymoquinone (TQ) (HY-D0803) with potent anti-breast cancer activity. TQFL13 exhibits higher cytotoxicity against breast cancer cells (BT549, MDA-MB-231, 4T1). TQFL13 increases apoptosis and blocks the cell cycle at S and G2/G1 phases in breast cancer cells. TQFL13 shows dose-dependent anti-tumor efficacy in mouse breast cancer allograft model. TQFL13 can be used for the study of breast cancer .
    TQFL13
  • HY-163849
    Mizoribine prodrug-1

    		Interleukin Related Inflammation/Immunology
    Mizoribine prodrug-1 (compound 18) is a oral active ester-based mizoribine (HY-17470) prodrug. Mizoribine prodrug-1 displays a inhibition of IL-2 production .
    Mizoribine prodrug-1
  • HY-163006
    EGFR/c-Met-IN-1

    		EGFR c-Met/HGFR Cancer
    EGFR/c-Met-IN-1 (compound TS-41) is a dual-target inhibitor of EGFR/c-Met. The IC50 for inhibiting EGFR L858R and c-Met is 68.1 nM and 0.26 nM respectively. . EGFR/c-Met-IN-1 induces apoptosis and cell cycle arrest in A549-P cells, downregulating the phosphorylation of EGFR, c-Met, and downstream AKT. EGFR/c-Met-IN-1 inhibits tumor growth in vitro and in vivo .
    EGFR/c-Met-IN-1
  • HY-170594
    Antitumor agent-192

    		Atg7 Autophagy Cancer
    Antitumor agent-192 (Compound 2f) is a β-carboline antitumor agent. Antitumor agent-192 induces autophagy in HCT116 cells via the ATG5/ATG7 pathway. Antitumor agent-192 has an IC50 of less than 5 μM for human tumor cell lines and significantly inhibits tumor development and reduces tumor weight in a mouse colorectal cancer model transplanted with allografts [1].
    Antitumor agent-192
  • HY-172874
    TDO-IN-2

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    TDO-IN-2 (Compound 5c) is an orally active TDO inhibitor (IC50: 1.25 μM). TDO-IN-2 has antitumor activity in the Hepa1-6 hepatocellular carcinoma allograft mouse model. TDO-IN-2 has synergistic effects with the PD-1/PD-L1 inhibitor BMS-202 (HY-19745) and can be used to study tumor immune tolerance .
    TDO-IN-2
  • HY-155523
    Tubulin/HDAC-IN-2

    		Microtubule/Tubulin HDAC Apoptosis Cancer
    Tubulin/HDAC-IN-2 (Compound II-19k) is a dual inhibitor of Tubulin and HDAC, with an IC50 of 0.403 μM, 0.591μM, 3.552μM, 0.459μM for HDAC1/2/3/6. Tubulin/HDAC-IN-2 blocks cell cycle arrest at G2 phase, induces cell apoptosis. Tubulin/HDAC-IN-2 inhibits the growth of hematoma and solid tumor cells, reduces tumor metastasis, and also inhibits tumor growth in a liver tumor allograft mouse model .
    Tubulin/HDAC-IN-2
  • HY-184134
    IDO1/TDO-IN-16

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1/TDO-IN-16 (Fig.1 Compound 4) is a dual inhibitor of IDO1 and TDO. IDO1/TDO-IN-16 is applicable for cancer research .
    IDO1/TDO-IN-16
  • HY-182241
    JR4-187

    		c-Myc Early 2 Factor (E2F) TNF Receptor MDM-2/p53 Reactive Oxygen Species (ROS) Apoptosis Cancer
    JR4-187 is an orally active, copper-dependent anticancer agent. JR4-187 downregulates genes involved in oxidative phosphorylation, MYC targets and E2F targets in cancer cells, while upregulates genes involved in the TNF-α signaling pathway, p53 pathway and KRAS signaling pathway, and downregulates CTR1 protein . JR4-187 induces ROS production, apoptosis, copper-dependent cytotoxicity, and exhibits selective cytotoxicity against KRAS-mutant cancer cells. JR4-187 is well tolerated in mouse models of pancreatic cancer. JR4-187 can be used in research related to cancers such as pancreatic ductal adenocarcinoma, colon cancer and rectal cancer .
    JR4-187

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: